17:14 , May 19, 2017 |  BioCentury  |  Strategy

Contracting 2.0

Pricing doesn’t always cause business discontinuities -- but it’s always the double-edged sword at the center of the action, helping innovators and hobbling laggards. Discount brokers revolutionized consumer investing; discounted long-distance ultimately destroyed AT&T. Price...
20:21 , Dec 16, 2016 |  BC Week In Review  |  Company News

Harvoni sales and marketing update

Express Scripts said it will expand the formulary of its Hepatitis Cure Value Program to include Gilead’s Harvoni ledipasvir/sofosbuvir. As part of an HCV pricing war, Harvoni had been kept out in favor of exclusive...
00:58 , Dec 13, 2016 |  BC Extra  |  Company News

Express Scripts adds Harvoni, expands indication-based pricing

Among a handful of changes revealed Monday, Express Scripts Holding Co. (NASDAQ:ESRX) said it will expand the formulary of its Hepatitis Cure Value Program to include Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD). As part...
07:00 , Oct 4, 2016 |  BC Extra  |  Company News

FDA adds warning to HCV drugs' labels

On Tuesday, FDA added a boxed warning to the labels of direct-acting antivirals for HCV. The warning describes the risk of reactivation of HBV infection in patients receiving the therapies. The agency said healthcare providers...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Exviera dasabuvir: Phase IIIb data

Top-line data from the open-label, international Phase IIIb GARNET trial in 163 treatment-naive patients with chronic HCV genotype 1b infection without cirrhosis showed that once-daily Viekirax ombitasvir/paritaprevir/ritonavir plus twice-daily Exviera dasabuvir without ribavirin for 8...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

Top-line data from the open-label, international Phase IIIb GARNET trial in 163 treatment-naive patients with chronic HCV genotype 1b infection without cirrhosis showed that once-daily Viekirax ombitasvir/paritaprevir/ritonavir plus twice-daily Exviera dasabuvir without ribavirin for 8...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Viekira XR ombitasvir/paritaprevir/ritonavir/dasabuvir regulatory update

FDA approved an NDA from AbbVie for Viekira XR ombitasvir/paritaprevir/ritonavir/dasabuvir to treat chronic HCV genotype 1 infection, including patients with compensated cirrhosis. Viekira XR is indicated for use without ribavirin in patients with HCV genotype...
07:00 , Aug 1, 2016 |  BC Extra  |  Politics & Policy

Express Scripts names 2017 exclusions, preferred drugs

On Monday, Express Scripts Holding Co. (NASDAQ:ESRX) posted a list of drugs it will not cover in its 2017 formulary, along with preferred alternatives in each drug category. The PBM will exclude from its formulary...
07:00 , Jul 29, 2016 |  BC Extra  |  Company News

Humira buoys AbbVie as HCV market share shrinks

AbbVie Inc. (NYSE:ABBV) reported 2Q16 financial results that beat estimates and raised full-year 2016 guidance. Continued strength in sales of autoimmune drug Humira adalimumab allayed some concerns about AbbVie's shrinking market share for its HCV...
07:00 , May 2, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/29 cls Dynavax Technologies Corp. (NASDAQ:DVAX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -26% $16.41 Simeonidis also...